Implication of Paraprobiotics in Age-Associated Gut Dysbiosis and Neurodegenerative Diseases

Neuromolecular Med. 2023 Mar;25(1):14-26. doi: 10.1007/s12017-022-08722-1. Epub 2022 Jul 25.

Abstract

Neurodegenerative diseases, including Alzheimer's and Parkinson's disease, are major age-related concerns in elderly people. Since no drug fully addresses the progression of neurodegenerative diseases, advance treatment strategies are urgently needed. Several studies have noted the senescence of immune system and the perturbation of gut microbiota in the aged population. In recent years, the role of gut microbiota has been increasingly studied in the manifestation of age-related CNS disorders. In this context, prebiotics, probiotics, and paraprobiotics are reported to improve the behavioural and neurobiological abnormalities in elderly patients. As live microbiota, prescribed in the form of probiotics, shows some adverse effects like sepsis, translocation, and horizontal gene transfer, paraprobiotics could be a possible alternative strategy in designing microbiome-based therapeutics. This review describes the health-beneficial effects of paraprobiotics in age-associated neurodegenerative diseases.

Keywords: Ageing; Alzheimer’s Disease; Gut dysbiosis; Neurodegenerative diseases; Paraprobiotics; Probiotics.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Dysbiosis / therapy
  • Gastrointestinal Microbiome*
  • Humans
  • Neurodegenerative Diseases* / therapy
  • Prebiotics
  • Probiotics* / therapeutic use

Substances

  • Prebiotics